- Home
- RMM vs SLGL Comparison
RMM vs SLGL Comparison
Compare RMM & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMM | SLGL |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.0M | 240.3M |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | RMM | SLGL |
|---|---|---|
| Price | $14.87 | $72.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 39.3K | 24.2K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.35 | $6.96 |
| 52 Week High | $14.98 | $97.97 |
Technical Indicators
Market Signals| Indicator | RMM | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 65.79 | 51.24 |
| Support Level | $13.87 | $70.05 |
| Resistance Level | $14.88 | $75.00 |
| Average True Range (ATR) | 0.20 | 4.78 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 83.08 | 39.73 |
Price Performance
Historical ComparisonAbout RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.